The drug that kills your appetite is killing your cravings too

GLP-1 is already repricing industries you can see. It is about to reprice ones you can't.

One Number

A weight-loss drug just cut heavy drinking by 41%. The alcohol industry has yet to take notice.  ·  The Lancet

On April 30, 2026, researchers at Copenhagen University Hospital published the first randomised controlled trial of semaglutide — the active ingredient in Wegovy and Ozempic — specifically for alcohol use disorder. Patients on the drug reduced their heavy drinking days by 41% over six months, against 26% in the placebo group. Heavy drinking days fell from 17 per month to five. This was not a weight study. It was a brain study. And it raises a question the alcohol industry has yet to answer.

One Argument

GLP-1 is not just a weight-loss drug. It is a reward drug.

GLP-1 has already caused disruption in several industries. Customers undergoing treatment are already spending 5.3% less on groceries, according to a Cornell study. JPMorgan expects USD 30-55bn annual food and beverage revenue reduction by 2030-2034. Revenues from bariatric surgery have decreased by 25.6% between 2022 and 2023, according to a Harvard study published in JAMA. Meanwhile, sales of apparel are projected by Bernstein to increase by USD 13bn with demand for formal-wear increasing 80%, according to Consumer Edge.

However, GLP-1 receptors exist not only in the gut but also in the brain’s reward system, which does not distinguish between food, alcohol, nicotine and opioids. GLP-1 dampens dopamine release across all of them. The Lancet alcohol result is the proof of concept. Trials are now being run across every addiction category, as stated by Eli Lilly’s CEO at the JPMorgan Healthcare Conference in January 2025. These are not four separate drug stories. It is one mechanism being systematically tested across four markets.

While the global GLP-1 market alone, according to The Economist, exceeded USD 26bn in 2025, the global alcohol use disorder treatment market was estimated at just USD 1.36bn. With only three medications for alcohol use disorder treatment approved over the last 75 years, this segment remains one of the most neglected large disease markets in medicine, according to The Lancet.

The alcohol industry has a clear public position. Molson Coors CEO Gavin Hattersley told investors in April 2024 that the company saw "no meaningful impact on the alcohol space." Carlsberg said the same in February 2026. Meanwhile, core beer fell below half of Carlsberg's revenue for the first time that year. Diageo's operating profit dropped 27.8% in the fiscal year to June 2025. Its alcohol-free portfolio grew 40% over the same period.

The consumer data is less reassuring. EY-Parthenon's March 2025 survey found 44% of GLP-1 users drink less after starting treatment. Among those cutting back, wine falls furthest — 52% reduced consumption — followed by beer at 43% and spirits at 40%. Morgan Stanley's analysis of third-party studies puts the potential reduction in alcohol consumption among all GLP-1 users at up to 75%, driven by 50% fewer occasions and 50% fewer drinks per occasion. The data already exists. The question is whether it is reaching the right boardrooms.

The Lancet study has based its findings on 108 patients, which is a small number by Phase 3 standards — the large-scale human trials required before a drug can seek regulatory approval. The US Food and Drug Administration approval process could take 3-6 years from Phase 3 launch. Meanwhile, global alcohol sales volumes have been declining at an annual rate of 1% since 2019, according to IWSR, with Generation Z driving much of the shift. Separating the GLP-1 impact from the broader moderation trend can be genuinely difficult.

The markets are pricing probability and not waiting for FDA approval. The Lancet result is the first randomised controlled trial, with Phase 3 now running in alcohol, nicotine and opioids simultaneously. EY-Parthenon research suggests that the behaviour change in GLP-1 users is durable — 82% maintain reduced drinking habits even after stopping treatment. A study of 1.3 million patients in 2025 concluded that GLP-1 users with alcohol use disorder had 50% fewer alcohol intoxication events over 2 years vs. non-users; those with opioid use disorder saw a 40% lower overdose rate over the same period.

One Position

The addiction angle is the GLP-1 story that is not yet in the price. Alcohol, tobacco, and gaming have the highest overlap with GLP-1 user demographics — affluent, health-conscious, over-40. However, these industries have the lowest acknowledgement of the structural risk they face. If your portfolio, your clients, or your counterparties have material exposure to any of these sectors, the question is not whether the drug changes the business. It is whether someone has modelled the scenario where 44% of the fastest-growing patient population is drinking less, and 82% stays that way after stopping treatment.

This position reverses if Phase 3 trials for semaglutide in alcohol use disorder fail to replicate the Lancet result. A 108-patient study is proof of concept, not conclusion. An unsuccessful Phase 3 removes the clinical foundation for behaviour change entirely.

If this was forwarded to you and you’d like to receive Corporate Financier’s Notes every Thursday, you can subscribe here.

Reading on your phone? Tap the three dots or overflow menu in the top corner of your email app and select View in browser for the best experience.

Corporate Financier’s Notes

Published every Thursday. One number, one argument, one position — for senior professionals who want to think - and sound - like a corporate financier.

© 2026 Corporate Financier’s Notes. All rights reserved. You are receiving this email because you subscribed to Corporate Financier’s Notes. If you no longer wish to receive these emails, you may unsubscribe at any time.